drugset / Trial / NCT02774044

Summary

The purpose of the study is to evaluate the efficacy and safety of Cadisurf (goat lung surfactant extract) as compared to Survanta (beractant) in the treatment of respiratory distress syndrome in preterm neonates (with gestation of 26 to 32 weeks).

Timeline

Start
2016-06
Primary completion
2019-02
Completion
2019-05

Outcome

Missed primary endpoint

paper There was no significant difference in the primary outcome of death or BPD between GLSE group (n = 52) and beractant group (n = 46) PMID 31485014 ↗

paper The need for repeat dose of surfactant was significantly higher in GLSE group (65.4 vs. 17.4%; OR 9.0; 95% CI 3.5-23.3; p < 0.001). PMID 31485014 ↗

Drugs

EvaluationDrugModalityDoseRoute
Comparator Beractant Other / unclassified 100 mg/kg Other
Subject Cadisurf Unknown 100 mg/kg Other